A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06730750
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986490 — DRUG
    Specified dose on specified days.
  • Bevacizumab — DRUG
    Specified dose on specified days.

Study Details

This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.

Key Dates

First listed
Dec 12, 2024
Start date
Feb 12, 2025
Status verified
Jul 2026
Primary completion
Sep 5, 2026
Completion
Dec 9, 2029

Study Design

Enrollment
360 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1A
  • Experimental: Part 2A - Colorectal Cancer (CRC)
  • Experimental: Part 2A - Non-Small Cell Lung Cancer/Gastric Cancer (NSCLC/GC)
  • Experimental: Part 1B
  • Experimental: Part 2B

Primary Outcome Measure

Number of participnats with Adverse Events (AEs) [ Time Frame: Up to 100 days following discontinuation of dosing ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (4)

FacilityCityStateZIPSite coordinators
Local Institution - 0007Los AngelesCalifornia90033-
Local Institution - 0017Grand RapidsMichigan49546-
Local Institution - 0004HackensackNew Jersey07601-
Local Institution - 0006PittsburghPennsylvania15232-

Find similar trials in Los Angeles, CA

By research site
Local Institution - 0007· Los Angeles, CALocal Institution - 0017· Grand Rapids, MILocal Institution - 0004· Hackensack, NJLocal Institution - 0006· Pittsburgh, PA

Related Studies